Compare · GILD vs SRZN
GILD vs SRZN
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Surrozen Inc. (SRZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SRZN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $153.66B, about 569.2x SRZN ($269.9M).
- Over the past year, GILD is up 16.4% and SRZN is up 128.9% - SRZN leads by 112.4 points.
- GILD has been more active in the news (16 items in the past 4 weeks vs 4 for SRZN).
- GILD has more recent analyst coverage (25 ratings vs 7 for SRZN).
- Company
- Gilead Sciences Inc.
- Surrozen Inc.
- Price
- $123.63-1.47%
- $22.66-4.75%
- Market cap
- $153.66B
- $269.9M
- 1M return
- -5.24%
- -12.10%
- 1Y return
- +16.45%
- +128.89%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 7
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Surrozen Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
Latest GILD
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
- National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
Latest SRZN
- Chief Financial Officer Maleki Andrew Pedrum was granted 607 shares (SEC Form 4)
- Exec. Vice President, Research Li Yang was granted 1,666 shares, increasing direct ownership by 10% to 18,882 units (SEC Form 4)
- Chief Operating Officer Williams Charles O was granted 1,666 shares, increasing direct ownership by 10% to 18,237 units (SEC Form 4)
- Chief Executive Officer Parker Craig C was granted 1,622 shares, increasing direct ownership by 10% to 18,175 units (SEC Form 4)
- SEC Form 4 filed by Director Kutzkey Tim
- Amendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.
- SEC Form 4 filed by Director Rothenberg Mace
- SEC Form 4 filed by Director Woodhouse David J